StockData

Akebia Therapeutics vs Ardelyx

AKBA and ARDX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AKBA and ARDX compare

Ardelyx is the larger company, worth 7.1 times as much as Akebia Therapeutics ($792M against $111M).

Ardelyx grew revenue faster over the last twelve months (16.8% versus 7.5% for Akebia Therapeutics).

Ardelyx keeps more of each dollar of sales as profit, with a net margin of −12.4% compared with −13.5% at Akebia Therapeutics.

Ardelyx scores higher on the StockData Score (9 against 6 for Akebia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAKBAARDX
Size and price
Market cap$111M$792M
Share price$0.400$3.18
Change, 1 year−76.0%−45.7%
Change, 5 years−85.0%256%
Beta (5Y)1.201.09
Employees194489
StockData Score
Total score69 (better)
Valuation score02 (better)
Growth score23 (better)
Performance score23 (better)
Health score2 (better)1
Dividend score00
Valuation
P/S0.5× (better)1.8×
P/B4.4× (better)5.3×
P/FCF2.8×–
FCF yield36.3% (better)−2.3%
Fair value–$7.61
Margin of safety–58.2%
Growth
Revenue growth (TTM)7.5%16.8% (better)
Revenue growth, 5Y average−4.3%122% (better)
Profitability
Gross margin79.6%94.4% (better)
Operating margin−6.9% (better)−7.9%
Net margin−13.5%−12.4% (better)
FCF margin18.4% (better)−4.0%
Return on equity−109%−38.6% (better)
Financial health
Debt / equity1.98–
Interest coverage–−1.6×
Current ratio1.433.34 (better)
Altman Z-score−5.89−0.10 (better)
Piotroski F-score7 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions39.7%71.2%
Held by insiders2.9%6.9%
Insider net buying, 12 months−$876K (better)−$1.9M
Short interest, % of float10.1%12.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.